Candesartan CAS 139481-59-7 Ubunyulu > 99.0% (HPLC) Factory
Ubonelelo lweMichiza yeRuifu Candesartan Cilexetil ePhakathi ngokucoceka okuphezulu
Candesartan Cilexetil CAS 145040-37-5
Candesartan CAS 139481-59-7
I-1-Chloroethyl Cyclohexyl Carbonate CAS 99464-83-2
Candesartan Cilexetil Phakathi Eethyl Ester C6 CAS 139481-41-7
Candesartan Cilexetil Intermediate CAS 139481-44-0
I-Trityl Candesartan Cilexetil CAS 170791-09-0
Igama leMchiza | Candesartan |
Izithethantonye | I-CV-11974;I-2-Ethoxy-1-[[2'- (1H-tetrazol-5-yl) [1,1'-biphenyl] -4-yl]methyl] -1H-Benzimidazole-7-Carboxylic Acid;3- [[2'- (1H-Tetrazol-5-yl) biphenyl-4-yl]methyl]-2-ethoxy-3H-Benzimidazole-4-Carboxylic Acid;iCandesartan M1;Candesartan Cilexetil EP Ukungcola G |
Inombolo yeCAS | 139481-59-7 |
Inombolo yeCAT | RF-PI1889 |
Ubume beStokhwe | Kwi-Stock, iMveliso yoMveliso ukuya kwiiToni |
Ifomula yeemolekyuli | I-C24H20N6O3 |
Ubunzima beMolekyuli | 440.45 |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Umgubo oMhlophe |
Ukuchongwa-HPLC | Ixesha lokuGcinwa lifana noMgangatho |
Ukuchongwa-IR | Iyafana noMgangatho |
Ubunyulu / Indlela yokuHlalutya | >99.0% (HPLC) |
Indawo yokunyibilika | 183.0 ~ 185.0℃ |
Ilahleko ekomisweni | <0.50% |
Ukufuma (KF) | <0.50% |
Intsalela kwi-Ignition | <0.50% |
Iintsimbi ezinzima | <20ppm |
Ukungacoceki komntu | <1.00% (HPLC) |
Ukungcola ngokupheleleyo | <1.00% (HPLC) |
Refractive Index | n20/D 1.745~1.747 |
Umgangatho woVavanyo | Umgangatho woShishino |
Ukusetyenziswa | API;KuNyango loxinzelelo lwegazi |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, 25kg/Igubu lekhadibhodi, okanye ngokwemfuno yomthengi
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ukukhanya kunye nokufuma
I-Candesartan (i-CAS: 139481-59-7) i-angiotensin II receptor antagonist kunye ne-IC50 ye-0.26 nM.Ithagethi: I-Angiotensin II Receptor candesartan iboniswa kunyango loxinzelelo lwegazi.I-Candesartan Cilexetil yavunywa okokuqala kwi-GB ngo-Apr 29, i-1997, emva koko yamkelwa yi-US Food and Drug Administration (FDA) ngoJuni 4, 1998, kwaye yamkelwa yi-Arhente ye-Pharmaceuticals and Medical Devices Agency yaseJapan (PMDA) ngo-Mar 12, 1999. Yaphuhliswa ngu-AstraZeneca, emva koko yathengiswa njenge-Atacand ngu-AstraZeneca kwi-GB kunye ne-US, kwaye ithengiswa njengeBlopress nguTakeda kwiJP.I-Candesartan Cilexetil yi-angiotensin II receptor blocker (ARB), ivimba i-vasoconstrictor kunye nemiphumo ye-aldosterone-secreting ye-angiotensin II ngokuthintela ngokukhethekileyo ukubopha i-angiotensin II kwi-receptor ye-AT1 kwiithishu ezininzi, ezifana ne-vascular smooth muscle kunye ne-adrenal gland.I-Atacand iboniswa kunyango lwe-hypertension kubantu abadala kunye nabantwana i-1 ukuya